Abstract:Objective Forty investigate the protective effect of Minocycline on 5-Fu induced intestinal mucostitis. Methods 40 male Balb/c mice were randomly divided into four groups (n = 10), Control group, 5-Fu induced mucositis model, high dose or low dose of Minocycline treated group. After the mice were intraperitoneal administrated with 80 mg/kg 5-Fu for 3 days and simultaneously treated with 30 or 60 mg/kg orally in Balb/c mice, the body weight loss, diarrhea scores, and HE stain of the intestinal, pro-inflammatory cytokines in intestine tissue and short chain fatty acids in colon contents were also determined. Results Data from this study indicated that high dose minocycline could attenuate the 5-Fu induced body weight loss (P < 0.01), and lower the diarrhea scores (P < 0.01). Also minicycline in high dose increased the intestinal vill length (P < 0.01), decreased the IL-6 (P < 0.05) and TNF-α (P < 0.01). In the colon contents, Minocycline could significantly increase the SCFAs concentration, especially for aceticacid butyricacid (P < 0.01). Conclusion All these results demonstrated that Minocycline exert protective effects on 5-Fu induced intestinal damage in mice, and these protective effects may partially oriented from its anti-inflammatory effects and enhancing short chain fatty acid production.
[1] Kengkla K,Kongpakwattana K,Saokaew S,et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections:a systematic review and network meta-analysis [J]. J Antimicrob Chemother,2018,73(1):22-32.
[2] Garrido-Mesa N,Zarzuelo A,Gálvez J. Minocycline: far beyond an antibiotic [J]. Br J Pharmacol,2013,169(2):337-352.
[3] Livermore DM,Mushtaq S,Warner M,et al. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii [J]. Antimicrob Agents Chemother,2016,60(6):3840-3844.
[4] Bahrami Z,Firouzi M,Hashemi-Monfared A,et al. The effect of minocycline on indolamine 2,3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia [J]. Cytokine,2018,107:125-129.
[5] Bonjoch L,Gea-Sorlí S,Jordan J,et al. Minocycline inhibits peritoneal macrophages but activates alveolar mac-rophages in acute pancreatitis [J]. J Physiol Biochem,2015,71(4):839-846.
[6] Aketa H,Tatsumi T,Kohga K,et al. The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice [J]. Int J Cancer,2013,133(5):1126-1134.
[7] Cheng M,Liu Z,Wan T,et al. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice [J]. Cancer Biol Ther,2012,13(14):1407-1416.
[8] Tang M,Lu X,Zhang C,et al. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer [J]. Theranostics,2017,7(5):1346-1359.
[9] Spencer NJ. Motility patterns in mouse colon:gastrointestinal dysfunction induced by anticancer chemotherapy [J]. Neurogastroenterol Motil,2016,28(12):1759-1764.
[10] Chang CT,Ho TY,Lin H,et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappa B activation by transcriptomic analysis and in vivo bioluminescence imaging [J]. PLoS One,2012,7(3):e31808.
[11] Zhang S,Liu Y,Xiang D,et al. Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury [J]. Biomed Pharmacother,2018,106:910-916.
[12] Ohkusa T,Yoshida T,Sato N,et al. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion:a possible pathogenic mechanism of ulcerative colitis [J]. J Med Microbiol,2009,58:535-545.
[13] Shimamura Y,Takeuchi I,Terada H,et al. A mouse model for oral mucositis induced by cancer chemotherapy [J]. Anticancer Res,2018,38(1):307-312.
[14] Pinto A,Fidalgo P,Cravo M,et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized,double-blind,controlled trial [J]. Dis Colon Rectum,1999,42(6):788-795,795-796.
[15] Ooi C,Good N,Williams D,et al. Efficacy of butyrate analogues in HT-29 cancer cells [J]. Clin Exp Pharmacol Physiol,2010,37(4):482-489.
[16] 傅红,师英强,莫善兢.短链脂肪酸对人结肠癌Caco-2细胞增殖分化的影响与临床意义[J].中华消化杂志,2003,23(8):473-475.
[17] Saif MW,Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency [J]. Cancer Chemother Pharmacol,2016,78(1):151-156.
[18] Yuan L,Zhang S,Li H,et al. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer [J]. Biomed Pharmacother,2018,108:184-193.
[19] Le Bastard Q,Ward T,Sidiropoulos D,et al. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice [J]. Sci Rep,2018,8(1):6219.
[20] Hamouda N,Sano T,Oikawa Y,et al. Apoptosis,dysbiosis and expression of inflammatory cytokines are sequential events in the development of 5-fluorouracil-induced intestinal mucositis in mice[J]. Basic Clin Pharmacol Toxicol,2017,121(3):159-168.